A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

Anthony W. Tolcher, Kim Chi, John Kuhn, Martin Gleave, Amita Patnaik, Chris Takimoto, Garry Schwartz, Ian Thompson, Kristin Berg, Susan D'Aloisio, Nevin Murray, Stanley R. Frankel, Elzbieta Izbicka, Eric Rowinsky

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy. Experimental Design: Patients with HRPC were treated with oblimersen sodium by continuous i.v. infusion on days 1 to 8 with docetaxel given i.v. over 1 hour on day 6 every 3 weeks. Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment. Results: Twenty-eight patients received 173 courses of oblimersen (7 mg/kg/d continuous i.v. infusion on days 1-8) and docetaxel (75 mg/m2 i.v. on day 6). Prostate-specific antigen responses were observed in 14 of 27 (52%) patients, whereas 4 of 12 (33%) patients with bidimensionally measurable disease had objective responses. The mean oblimersen steady-state concentration (Css) was a significant determinant of antitumor activity; mean Css values were higher in responders compared with nonresponders (6.24 ± 1.68 versus 4.27 ± 1.22; P = 0.008). The median survival of all patients was 19.8 months. Bcl-2 protein expression decreased a median of 49.9% in peripheral blood mononuclear cells post-treatment, but the individual incremental change did not correlate with either oblimersen Css or response. Conclusions: Oblimersen combined with docetaxel is an active combination in HRPC patients demonstrating both an encouraging response rate and an overall median survival. The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination, including studies to optimize oblimersen Css.

Original languageEnglish (US)
Pages (from-to)3854-3861
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number10
DOIs
StatePublished - May 15 2005

Fingerprint

docetaxel
Prostatic Neoplasms
Pharmacokinetics
Hormones
Blood Cells
Phosphorothioate Oligonucleotides
oblimersen
Proteins
Survival
Antisense Oligonucleotides
Prostate-Specific Antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. / Tolcher, Anthony W.; Chi, Kim; Kuhn, John; Gleave, Martin; Patnaik, Amita; Takimoto, Chris; Schwartz, Garry; Thompson, Ian; Berg, Kristin; D'Aloisio, Susan; Murray, Nevin; Frankel, Stanley R.; Izbicka, Elzbieta; Rowinsky, Eric.

In: Clinical Cancer Research, Vol. 11, No. 10, 15.05.2005, p. 3854-3861.

Research output: Contribution to journalArticle

Tolcher, AW, Chi, K, Kuhn, J, Gleave, M, Patnaik, A, Takimoto, C, Schwartz, G, Thompson, I, Berg, K, D'Aloisio, S, Murray, N, Frankel, SR, Izbicka, E & Rowinsky, E 2005, 'A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer', Clinical Cancer Research, vol. 11, no. 10, pp. 3854-3861. https://doi.org/10.1158/1078-0432.CCR-04-2145
Tolcher, Anthony W. ; Chi, Kim ; Kuhn, John ; Gleave, Martin ; Patnaik, Amita ; Takimoto, Chris ; Schwartz, Garry ; Thompson, Ian ; Berg, Kristin ; D'Aloisio, Susan ; Murray, Nevin ; Frankel, Stanley R. ; Izbicka, Elzbieta ; Rowinsky, Eric. / A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 10. pp. 3854-3861.
@article{0f722b8989a04a64a60b1ee5929c2744,
title = "A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer",
abstract = "Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy. Experimental Design: Patients with HRPC were treated with oblimersen sodium by continuous i.v. infusion on days 1 to 8 with docetaxel given i.v. over 1 hour on day 6 every 3 weeks. Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment. Results: Twenty-eight patients received 173 courses of oblimersen (7 mg/kg/d continuous i.v. infusion on days 1-8) and docetaxel (75 mg/m2 i.v. on day 6). Prostate-specific antigen responses were observed in 14 of 27 (52{\%}) patients, whereas 4 of 12 (33{\%}) patients with bidimensionally measurable disease had objective responses. The mean oblimersen steady-state concentration (Css) was a significant determinant of antitumor activity; mean Css values were higher in responders compared with nonresponders (6.24 ± 1.68 versus 4.27 ± 1.22; P = 0.008). The median survival of all patients was 19.8 months. Bcl-2 protein expression decreased a median of 49.9{\%} in peripheral blood mononuclear cells post-treatment, but the individual incremental change did not correlate with either oblimersen Css or response. Conclusions: Oblimersen combined with docetaxel is an active combination in HRPC patients demonstrating both an encouraging response rate and an overall median survival. The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination, including studies to optimize oblimersen Css.",
author = "Tolcher, {Anthony W.} and Kim Chi and John Kuhn and Martin Gleave and Amita Patnaik and Chris Takimoto and Garry Schwartz and Ian Thompson and Kristin Berg and Susan D'Aloisio and Nevin Murray and Frankel, {Stanley R.} and Elzbieta Izbicka and Eric Rowinsky",
year = "2005",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-04-2145",
language = "English (US)",
volume = "11",
pages = "3854--3861",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

AU - Tolcher, Anthony W.

AU - Chi, Kim

AU - Kuhn, John

AU - Gleave, Martin

AU - Patnaik, Amita

AU - Takimoto, Chris

AU - Schwartz, Garry

AU - Thompson, Ian

AU - Berg, Kristin

AU - D'Aloisio, Susan

AU - Murray, Nevin

AU - Frankel, Stanley R.

AU - Izbicka, Elzbieta

AU - Rowinsky, Eric

PY - 2005/5/15

Y1 - 2005/5/15

N2 - Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy. Experimental Design: Patients with HRPC were treated with oblimersen sodium by continuous i.v. infusion on days 1 to 8 with docetaxel given i.v. over 1 hour on day 6 every 3 weeks. Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment. Results: Twenty-eight patients received 173 courses of oblimersen (7 mg/kg/d continuous i.v. infusion on days 1-8) and docetaxel (75 mg/m2 i.v. on day 6). Prostate-specific antigen responses were observed in 14 of 27 (52%) patients, whereas 4 of 12 (33%) patients with bidimensionally measurable disease had objective responses. The mean oblimersen steady-state concentration (Css) was a significant determinant of antitumor activity; mean Css values were higher in responders compared with nonresponders (6.24 ± 1.68 versus 4.27 ± 1.22; P = 0.008). The median survival of all patients was 19.8 months. Bcl-2 protein expression decreased a median of 49.9% in peripheral blood mononuclear cells post-treatment, but the individual incremental change did not correlate with either oblimersen Css or response. Conclusions: Oblimersen combined with docetaxel is an active combination in HRPC patients demonstrating both an encouraging response rate and an overall median survival. The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination, including studies to optimize oblimersen Css.

AB - Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy. Experimental Design: Patients with HRPC were treated with oblimersen sodium by continuous i.v. infusion on days 1 to 8 with docetaxel given i.v. over 1 hour on day 6 every 3 weeks. Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment. Results: Twenty-eight patients received 173 courses of oblimersen (7 mg/kg/d continuous i.v. infusion on days 1-8) and docetaxel (75 mg/m2 i.v. on day 6). Prostate-specific antigen responses were observed in 14 of 27 (52%) patients, whereas 4 of 12 (33%) patients with bidimensionally measurable disease had objective responses. The mean oblimersen steady-state concentration (Css) was a significant determinant of antitumor activity; mean Css values were higher in responders compared with nonresponders (6.24 ± 1.68 versus 4.27 ± 1.22; P = 0.008). The median survival of all patients was 19.8 months. Bcl-2 protein expression decreased a median of 49.9% in peripheral blood mononuclear cells post-treatment, but the individual incremental change did not correlate with either oblimersen Css or response. Conclusions: Oblimersen combined with docetaxel is an active combination in HRPC patients demonstrating both an encouraging response rate and an overall median survival. The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination, including studies to optimize oblimersen Css.

UR - http://www.scopus.com/inward/record.url?scp=21044431880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044431880&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2145

DO - 10.1158/1078-0432.CCR-04-2145

M3 - Article

C2 - 15897586

AN - SCOPUS:21044431880

VL - 11

SP - 3854

EP - 3861

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -